Editorial: LRRK2-Fifteen Years From Cloning to the Clinic

Front Neurosci. 2022 Apr 11:16:880914. doi: 10.3389/fnins.2022.880914. eCollection 2022.

Hardy Rideout¹, Elisa Greggio², Arjan Kortholt^{3

4

5}, R Jeremy Nichols⁶

¹ Biomedical Research Foundation of the Academy of Athens, Athens, Greece.
² Department of Biology, University of Padova, Padua, Italy.
³ Department of Cell Biochemistry, University of Groningen, Groningen, Netherlands.
⁴ YETEM-Innovative Technologies Application and Research Centre, Suleyman Demirel University, Isparta, Turkey.
⁵ Centro Studi per la Neurodegenerazione (CESNE), University of Padova, Italy.
⁶ Department of Pathology, Stanford University, Stanford, CA, United States.

No abstract available

Keywords: LRRK2; Parkinson's disease; alpha-synuclein; biomarker; endosome; kinase; lysosome; phosphorylation.

Publication types